{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Overall survival is defined as the interval from randomization to death from any cause.","groups":[{"description":"Idelalisib 150 mg tablet twice daily + bendamustine intravenously (starting dose of 90 mg/m\\^2 for up to 12 infusions) + rituximab intravenously (375 mg/m\\^2 on Day 1 for a total of 6 infusions)","id":"OG000","title":"Idelalisib + Bendamustine + Rituximab"},{"description":"Placebo tablet twice daily + bendamustine intravenously (starting dose of 90 mg/m\\^2 for up to 12 infusions) + rituximab intravenously (375 mg/m\\^2 on Day 1 for a total of 6 infusions)","id":"OG001","title":"Placebo + Bendamustine + Rituximab"}],"populationDescription":"Due to the early termination of the study, efficacy data were not mature for all participants, and therefore the prespecified analyses were not conducted.","reportingStatus":"POSTED","title":"Overall Survival (OS)","type":"SECONDARY"}